SrasV1, PascalFrancis, Curation, bibRecord, 000542

Antiviral drug discovery against SARS-CoV

Identifieur interne : 000542 ( PascalFrancis/Curation ); précédent : 000541; suivant : 000543

Antiviral drug discovery against SARS-CoV

Auteurs : Yu-Shan Wu [Taïwan] ; Wen-Hsing Lin [Taïwan] ; John T.-A. Hsu [Taïwan] ; Hsing-Pang Flsieh [Taïwan]

Source :

Current medicinal chemistry [ 0929-8673 ] ; 2006.

RBID : Pascal:06-0496072

Descripteurs français

Pascal (Inist)
- Antiviral, Recherche développement, Médicament, Virus syndrome respiratoire aigu sévère, Article synthèse, Criblage haut débit, Ciblage, Synthèse chimique, Peptide, Analogue, Composé non peptide, Inhibiteur protease, siRNA, Relation structure activité, Inhibiteur enzyme, Peptidases, RNA antisens, Criblage virtuel.
Wicri :
- topic : Médicament.

English descriptors

KwdEn :
- Analog, Antisense RNA, Antiviral, Chemical synthesis, Drug, Enzyme inhibitor, High throughput screening, Non peptide compound, Peptidases, Peptides, Protease inhibitor, Research and development, Review, Severe acute respiratory syndrome virus, Small Interference RNA, Structure activity relation, Targeting, Virtual screening.

Abstract

Severe Acute Respiratory Syndrome (SARS) is a life-threatening infectious disease caused by SARS-CoV. In the 2003 outbreak, it infected more than 8,000 people worldwide and claimed the lives of more than 900 victims. The high mortality rate resulted, at least in part, from the absence of definitive treatment protocols or therapeutic agents. Although the virus spreading has been contained, due preparedness and planning, including the successful development of antiviral drugs against SARS-CoV, is necessary for possible reappearance of SARS. In this review, we have discussed currently available strategies for antiviral drug discovery and how these technologies have been utilized to identify potential antiviral agents for the inhibition of SARS-CoV replication. Moreover, progress in the drug development based on different molecular targets is also summarized, including 1) Compounds that block the S protein-ACE2-mediated viral entry; 2) Compounds targeting SARS-CoV M^pro; 3) Compounds targeting papain-like protease 2 (PLP2); 4) Compounds targeting SARS-CoV RdRp; 5) Compounds targeting SARS-CoV helicase; 6) Active compounds with unspecified targets; and 7) Research on siRNA. This review aims to provide a comprehensive account of drug discovery on SARS. The experiences with the SARS outbreak and drug discovery would certainly be an important lesson for the drug development for any new viral outbreaks that may emerge in the future.

A01	`01`	`1`		`@0 0929-8673`
A03		`1`		`@0 Curr. med. chem.`
A05				`@2 13`
A06				`@2 17`
A08	`01`	`1`	`ENG`	`@1 Antiviral drug discovery against SARS-CoV`
A11	`01`	`1`		`@1 WU (Yu-Shan)`
A11	`02`	`1`		`@1 LIN (Wen-Hsing)`
A11	`03`	`1`		`@1 HSU (John T.-A.)`
A11	`04`	`1`		`@1 FLSIEH (Hsing-Pang)`
A14	`01`			`@1 Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes @2 Miaoli County @3 TWN @Z 1 aut. @Z 2 aut. @Z 3 aut. @Z 4 aut.`
A14	`02`			`@1 Department of Chemical Engineering, National Tsing Hua University @2 Hsinchu @3 TWN @Z 3 aut.`
A20				`@1 2003-2020`
A21				`@1 2006`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 22999 @5 354000142403870040`
A44				`@0 0000 @1 © 2006 INIST-CNRS. All rights reserved.`
A45				`@0 110 ref.`
A47	`01`	`1`		`@0 06-0496072`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Current medicinal chemistry`
A66	`01`			`@0 NLD`
C01	`01`		`ENG`	@0 Severe Acute Respiratory Syndrome (SARS) is a life-threatening infectious disease caused by SARS-CoV. In the 2003 outbreak, it infected more than 8,000 people worldwide and claimed the lives of more than 900 victims. The high mortality rate resulted, at least in part, from the absence of definitive treatment protocols or therapeutic agents. Although the virus spreading has been contained, due preparedness and planning, including the successful development of antiviral drugs against SARS-CoV, is necessary for possible reappearance of SARS. In this review, we have discussed currently available strategies for antiviral drug discovery and how these technologies have been utilized to identify potential antiviral agents for the inhibition of SARS-CoV replication. Moreover, progress in the drug development based on different molecular targets is also summarized, including 1) Compounds that block the S protein-ACE2-mediated viral entry; 2) Compounds targeting SARS-CoV M^pro; 3) Compounds targeting papain-like protease 2 (PLP2); 4) Compounds targeting SARS-CoV RdRp; 5) Compounds targeting SARS-CoV helicase; 6) Active compounds with unspecified targets; and 7) Research on siRNA. This review aims to provide a comprehensive account of drug discovery on SARS. The experiences with the SARS outbreak and drug discovery would certainly be an important lesson for the drug development for any new viral outbreaks that may emerge in the future.
C02	`01`	`X`		`@0 002B02S05`
C03	`01`	`X`	`FRE`	`@0 Antiviral @5 01`
C03	`01`	`X`	`ENG`	`@0 Antiviral @5 01`
C03	`01`	`X`	`SPA`	`@0 Antiviral @5 01`
C03	`02`	`X`	`FRE`	`@0 Recherche développement @5 02`
C03	`02`	`X`	`ENG`	`@0 Research and development @5 02`
C03	`02`	`X`	`SPA`	`@0 Investigación desarrollo @5 02`
C03	`03`	`X`	`FRE`	`@0 Médicament @5 03`
C03	`03`	`X`	`ENG`	`@0 Drug @5 03`
C03	`03`	`X`	`SPA`	`@0 Medicamento @5 03`
C03	`04`	`X`	`FRE`	`@0 Virus syndrome respiratoire aigu sévère @2 NW @5 04`
C03	`04`	`X`	`ENG`	`@0 Severe acute respiratory syndrome virus @2 NW @5 04`
C03	`04`	`X`	`SPA`	`@0 Severe acute respiratory syndrome virus @2 NW @5 04`
C03	`05`	`X`	`FRE`	`@0 Article synthèse @5 05`
C03	`05`	`X`	`ENG`	`@0 Review @5 05`
C03	`05`	`X`	`SPA`	`@0 Artículo síntesis @5 05`
C03	`06`	`X`	`FRE`	`@0 Criblage haut débit @5 06`
C03	`06`	`X`	`ENG`	`@0 High throughput screening @5 06`
C03	`06`	`X`	`SPA`	`@0 Cribado alta productividad @5 06`
C03	`07`	`X`	`FRE`	`@0 Ciblage @5 07`
C03	`07`	`X`	`ENG`	`@0 Targeting @5 07`
C03	`07`	`X`	`SPA`	`@0 Blancado @5 07`
C03	`08`	`X`	`FRE`	`@0 Synthèse chimique @5 08`
C03	`08`	`X`	`ENG`	`@0 Chemical synthesis @5 08`
C03	`08`	`X`	`SPA`	`@0 Síntesis química @5 08`
C03	`09`	`X`	`FRE`	`@0 Peptide @5 09`
C03	`09`	`X`	`ENG`	`@0 Peptides @5 09`
C03	`09`	`X`	`SPA`	`@0 Péptido @5 09`
C03	`10`	`X`	`FRE`	`@0 Analogue @5 10`
C03	`10`	`X`	`ENG`	`@0 Analog @5 10`
C03	`10`	`X`	`SPA`	`@0 Análogo @5 10`
C03	`11`	`X`	`FRE`	`@0 Composé non peptide @5 11`
C03	`11`	`X`	`ENG`	`@0 Non peptide compound @5 11`
C03	`11`	`X`	`SPA`	`@0 Compuesto no péptido @5 11`
C03	`12`	`X`	`FRE`	`@0 Inhibiteur protease @2 FR @5 12`
C03	`12`	`X`	`ENG`	`@0 Protease inhibitor @2 FR @5 12`
C03	`12`	`X`	`SPA`	`@0 Inhibidor proteasa @2 FR @5 12`
C03	`13`	`X`	`FRE`	`@0 siRNA @5 13`
C03	`13`	`X`	`ENG`	`@0 Small Interference RNA @5 13`
C03	`13`	`X`	`SPA`	`@0 siRNA @5 13`
C03	`14`	`X`	`FRE`	`@0 Relation structure activité @5 14`
C03	`14`	`X`	`ENG`	`@0 Structure activity relation @5 14`
C03	`14`	`X`	`SPA`	`@0 Relación estructura actividad @5 14`
C03	`15`	`X`	`FRE`	`@0 Inhibiteur enzyme @5 32`
C03	`15`	`X`	`ENG`	`@0 Enzyme inhibitor @5 32`
C03	`15`	`X`	`SPA`	`@0 Inhibidor enzima @5 32`
C03	`16`	`X`	`FRE`	`@0 Peptidases @2 FE @5 33`
C03	`16`	`X`	`ENG`	`@0 Peptidases @2 FE @5 33`
C03	`16`	`X`	`SPA`	`@0 Peptidases @2 FE @5 33`
C03	`17`	`X`	`FRE`	`@0 RNA antisens @5 35`
C03	`17`	`X`	`ENG`	`@0 Antisense RNA @5 35`
C03	`17`	`X`	`SPA`	`@0 RNA antisentido @5 35`
C03	`18`	`X`	`FRE`	`@0 Criblage virtuel @4 CD @5 96`
C03	`18`	`X`	`ENG`	`@0 Virtual screening @4 CD @5 96`
C03	`18`	`X`	`SPA`	`@0 Cribado virtual @4 CD @5 96`
C07	`01`	`X`	`FRE`	`@0 Coronavirus @2 NW`
C07	`01`	`X`	`ENG`	`@0 Coronavirus @2 NW`
C07	`01`	`X`	`SPA`	`@0 Coronavirus @2 NW`
C07	`02`	`X`	`FRE`	`@0 Coronaviridae @2 NW`
C07	`02`	`X`	`ENG`	`@0 Coronaviridae @2 NW`
C07	`02`	`X`	`SPA`	`@0 Coronaviridae @2 NW`
C07	`03`	`X`	`FRE`	`@0 Nidovirales @2 NW`
C07	`03`	`X`	`ENG`	`@0 Nidovirales @2 NW`
C07	`03`	`X`	`SPA`	`@0 Nidovirales @2 NW`
C07	`04`	`X`	`FRE`	`@0 Virus @2 NW`
C07	`04`	`X`	`ENG`	`@0 Virus @2 NW`
C07	`04`	`X`	`SPA`	`@0 Virus @2 NW`
C07	`05`	`X`	`FRE`	`@0 Hydrolases @2 FE`
C07	`05`	`X`	`ENG`	`@0 Hydrolases @2 FE`
C07	`05`	`X`	`SPA`	`@0 Hydrolases @2 FE`
C07	`06`	`X`	`FRE`	`@0 Enzyme @2 FE`
C07	`06`	`X`	`ENG`	`@0 Enzyme @2 FE`
C07	`06`	`X`	`SPA`	`@0 Enzima @2 FE`
N21				`@1 324`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000448

Links to Exploration step

Pascal:06-0496072

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Antiviral drug discovery against SARS-CoV</title>
<author><name sortKey="Wu, Yu Shan" sort="Wu, Yu Shan" uniqKey="Wu Y" first="Yu-Shan" last="Wu">Yu-Shan Wu</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes</s1>
<s2>Miaoli County</s2>
<s3>TWN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Taïwan</country>
</affiliation>
</author>
<author><name sortKey="Lin, Wen Hsing" sort="Lin, Wen Hsing" uniqKey="Lin W" first="Wen-Hsing" last="Lin">Wen-Hsing Lin</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes</s1>
<s2>Miaoli County</s2>
<s3>TWN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Taïwan</country>
</affiliation>
</author>
<author><name sortKey="Hsu, John T A" sort="Hsu, John T A" uniqKey="Hsu J" first="John T.-A." last="Hsu">John T.-A. Hsu</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes</s1>
<s2>Miaoli County</s2>
<s3>TWN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Taïwan</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Chemical Engineering, National Tsing Hua University</s1>
<s2>Hsinchu</s2>
<s3>TWN</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Taïwan</country>
</affiliation>
</author>
<author><name sortKey="Flsieh, Hsing Pang" sort="Flsieh, Hsing Pang" uniqKey="Flsieh H" first="Hsing-Pang" last="Flsieh">Hsing-Pang Flsieh</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes</s1>
<s2>Miaoli County</s2>
<s3>TWN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Taïwan</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">06-0496072</idno>
<date when="2006">2006</date>
<idno type="stanalyst">PASCAL 06-0496072 INIST</idno>
<idno type="RBID">Pascal:06-0496072</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000448</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000542</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Antiviral drug discovery against SARS-CoV</title>
<author><name sortKey="Wu, Yu Shan" sort="Wu, Yu Shan" uniqKey="Wu Y" first="Yu-Shan" last="Wu">Yu-Shan Wu</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes</s1>
<s2>Miaoli County</s2>
<s3>TWN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Taïwan</country>
</affiliation>
</author>
<author><name sortKey="Lin, Wen Hsing" sort="Lin, Wen Hsing" uniqKey="Lin W" first="Wen-Hsing" last="Lin">Wen-Hsing Lin</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes</s1>
<s2>Miaoli County</s2>
<s3>TWN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Taïwan</country>
</affiliation>
</author>
<author><name sortKey="Hsu, John T A" sort="Hsu, John T A" uniqKey="Hsu J" first="John T.-A." last="Hsu">John T.-A. Hsu</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes</s1>
<s2>Miaoli County</s2>
<s3>TWN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Taïwan</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Chemical Engineering, National Tsing Hua University</s1>
<s2>Hsinchu</s2>
<s3>TWN</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Taïwan</country>
</affiliation>
</author>
<author><name sortKey="Flsieh, Hsing Pang" sort="Flsieh, Hsing Pang" uniqKey="Flsieh H" first="Hsing-Pang" last="Flsieh">Hsing-Pang Flsieh</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes</s1>
<s2>Miaoli County</s2>
<s3>TWN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Taïwan</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Current medicinal chemistry</title>
<title level="j" type="abbreviated">Curr. med. chem.</title>
<idno type="ISSN">0929-8673</idno>
<imprint><date when="2006">2006</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Current medicinal chemistry</title>
<title level="j" type="abbreviated">Curr. med. chem.</title>
<idno type="ISSN">0929-8673</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Analog</term>
<term>Antisense RNA</term>
<term>Antiviral</term>
<term>Chemical synthesis</term>
<term>Drug</term>
<term>Enzyme inhibitor</term>
<term>High throughput screening</term>
<term>Non peptide compound</term>
<term>Peptidases</term>
<term>Peptides</term>
<term>Protease inhibitor</term>
<term>Research and development</term>
<term>Review</term>
<term>Severe acute respiratory syndrome virus</term>
<term>Small Interference RNA</term>
<term>Structure activity relation</term>
<term>Targeting</term>
<term>Virtual screening</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Antiviral</term>
<term>Recherche développement</term>
<term>Médicament</term>
<term>Virus syndrome respiratoire aigu sévère</term>
<term>Article synthèse</term>
<term>Criblage haut débit</term>
<term>Ciblage</term>
<term>Synthèse chimique</term>
<term>Peptide</term>
<term>Analogue</term>
<term>Composé non peptide</term>
<term>Inhibiteur protease</term>
<term>siRNA</term>
<term>Relation structure activité</term>
<term>Inhibiteur enzyme</term>
<term>Peptidases</term>
<term>RNA antisens</term>
<term>Criblage virtuel</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Médicament</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Severe Acute Respiratory Syndrome (SARS) is a life-threatening infectious disease caused by SARS-CoV. In the 2003 outbreak, it infected more than 8,000 people worldwide and claimed the lives of more than 900 victims. The high mortality rate resulted, at least in part, from the absence of definitive treatment protocols or therapeutic agents. Although the virus spreading has been contained, due preparedness and planning, including the successful development of antiviral drugs against SARS-CoV, is necessary for possible reappearance of SARS. In this review, we have discussed currently available strategies for antiviral drug discovery and how these technologies have been utilized to identify potential antiviral agents for the inhibition of SARS-CoV replication. Moreover, progress in the drug development based on different molecular targets is also summarized, including 1) Compounds that block the S protein-ACE2-mediated viral entry; 2) Compounds targeting SARS-CoV M<sup>pro</sup>
; 3) Compounds targeting papain-like protease 2 (PLP2); 4) Compounds targeting SARS-CoV RdRp; 5) Compounds targeting SARS-CoV helicase; 6) Active compounds with unspecified targets; and 7) Research on siRNA. This review aims to provide a comprehensive account of drug discovery on SARS. The experiences with the SARS outbreak and drug discovery would certainly be an important lesson for the drug development for any new viral outbreaks that may emerge in the future.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0929-8673</s0>
</fA01>
<fA03 i2="1"><s0>Curr. med. chem.</s0>
</fA03>
<fA05><s2>13</s2>
</fA05>
<fA06><s2>17</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Antiviral drug discovery against SARS-CoV</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>WU (Yu-Shan)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>LIN (Wen-Hsing)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>HSU (John T.-A.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>FLSIEH (Hsing-Pang)</s1>
</fA11>
<fA14 i1="01"><s1>Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes</s1>
<s2>Miaoli County</s2>
<s3>TWN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Department of Chemical Engineering, National Tsing Hua University</s1>
<s2>Hsinchu</s2>
<s3>TWN</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA20><s1>2003-2020</s1>
</fA20>
<fA21><s1>2006</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>22999</s2>
<s5>354000142403870040</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2006 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>110 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>06-0496072</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Current medicinal chemistry</s0>
</fA64>
<fA66 i1="01"><s0>NLD</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Severe Acute Respiratory Syndrome (SARS) is a life-threatening infectious disease caused by SARS-CoV. In the 2003 outbreak, it infected more than 8,000 people worldwide and claimed the lives of more than 900 victims. The high mortality rate resulted, at least in part, from the absence of definitive treatment protocols or therapeutic agents. Although the virus spreading has been contained, due preparedness and planning, including the successful development of antiviral drugs against SARS-CoV, is necessary for possible reappearance of SARS. In this review, we have discussed currently available strategies for antiviral drug discovery and how these technologies have been utilized to identify potential antiviral agents for the inhibition of SARS-CoV replication. Moreover, progress in the drug development based on different molecular targets is also summarized, including 1) Compounds that block the S protein-ACE2-mediated viral entry; 2) Compounds targeting SARS-CoV M<sup>pro</sup>
; 3) Compounds targeting papain-like protease 2 (PLP2); 4) Compounds targeting SARS-CoV RdRp; 5) Compounds targeting SARS-CoV helicase; 6) Active compounds with unspecified targets; and 7) Research on siRNA. This review aims to provide a comprehensive account of drug discovery on SARS. The experiences with the SARS outbreak and drug discovery would certainly be an important lesson for the drug development for any new viral outbreaks that may emerge in the future.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B02S05</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Antiviral</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Antiviral</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Antiviral</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Recherche développement</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Research and development</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Investigación desarrollo</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Médicament</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Drug</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Medicamento</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Virus syndrome respiratoire aigu sévère</s0>
<s2>NW</s2>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Severe acute respiratory syndrome virus</s0>
<s2>NW</s2>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Severe acute respiratory syndrome virus</s0>
<s2>NW</s2>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Article synthèse</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Review</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Artículo síntesis</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Criblage haut débit</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>High throughput screening</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Cribado alta productividad</s0>
<s5>06</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Ciblage</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Targeting</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Blancado</s0>
<s5>07</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Synthèse chimique</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Chemical synthesis</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Síntesis química</s0>
<s5>08</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Peptide</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Peptides</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Péptido</s0>
<s5>09</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Analogue</s0>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Analog</s0>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Análogo</s0>
<s5>10</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Composé non peptide</s0>
<s5>11</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Non peptide compound</s0>
<s5>11</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Compuesto no péptido</s0>
<s5>11</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Inhibiteur protease</s0>
<s2>FR</s2>
<s5>12</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Protease inhibitor</s0>
<s2>FR</s2>
<s5>12</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Inhibidor proteasa</s0>
<s2>FR</s2>
<s5>12</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>siRNA</s0>
<s5>13</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG"><s0>Small Interference RNA</s0>
<s5>13</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA"><s0>siRNA</s0>
<s5>13</s5>
</fC03>
<fC03 i1="14" i2="X" l="FRE"><s0>Relation structure activité</s0>
<s5>14</s5>
</fC03>
<fC03 i1="14" i2="X" l="ENG"><s0>Structure activity relation</s0>
<s5>14</s5>
</fC03>
<fC03 i1="14" i2="X" l="SPA"><s0>Relación estructura actividad</s0>
<s5>14</s5>
</fC03>
<fC03 i1="15" i2="X" l="FRE"><s0>Inhibiteur enzyme</s0>
<s5>32</s5>
</fC03>
<fC03 i1="15" i2="X" l="ENG"><s0>Enzyme inhibitor</s0>
<s5>32</s5>
</fC03>
<fC03 i1="15" i2="X" l="SPA"><s0>Inhibidor enzima</s0>
<s5>32</s5>
</fC03>
<fC03 i1="16" i2="X" l="FRE"><s0>Peptidases</s0>
<s2>FE</s2>
<s5>33</s5>
</fC03>
<fC03 i1="16" i2="X" l="ENG"><s0>Peptidases</s0>
<s2>FE</s2>
<s5>33</s5>
</fC03>
<fC03 i1="16" i2="X" l="SPA"><s0>Peptidases</s0>
<s2>FE</s2>
<s5>33</s5>
</fC03>
<fC03 i1="17" i2="X" l="FRE"><s0>RNA antisens</s0>
<s5>35</s5>
</fC03>
<fC03 i1="17" i2="X" l="ENG"><s0>Antisense RNA</s0>
<s5>35</s5>
</fC03>
<fC03 i1="17" i2="X" l="SPA"><s0>RNA antisentido</s0>
<s5>35</s5>
</fC03>
<fC03 i1="18" i2="X" l="FRE"><s0>Criblage virtuel</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC03 i1="18" i2="X" l="ENG"><s0>Virtual screening</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC03 i1="18" i2="X" l="SPA"><s0>Cribado virtual</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Coronavirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Coronavirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Coronavirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Hydrolases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Hydrolases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Hydrolases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Enzyme</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Enzyme</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Enzima</s0>
<s2>FE</s2>
</fC07>
<fN21><s1>324</s1>
</fN21>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000542 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 000542 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:06-0496072
   |texte=   Antiviral drug discovery against SARS-CoV
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration SRAS

Antiviral drug discovery against SARS-CoV

Antiviral drug discovery against SARS-CoV

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri